CAPRISA Vaccine team recognised for excellence

30 August 2019

Two landmark HIV vaccine trials, the HVTN 702 (Uhambo) and HVTN 705 (Imbokodo) efficacy trials successfully completed enrolments earlier this year.  The HVTN 702 trial, investigating a clade C vaccine, enrolled a total of 5407 men and women from South Africa, while HVTN 705, a mosaic vaccine trial, recruited 2622 young women from across Africa. Dr Nivashnee Naicker (Site-Principal Investigator for HVTN702) said that the CAPRISA team at the eThekwini Research Clinic made a substantial contribution by enrolling more than 400 participants into these trials. The team was acknowledged at the Full Group Meeting held in Washington where they received awards for ‘Excellent Data Submission’ and high participant retention. Dr Nigel Garrett, Head of Pathogenesis and Vaccine Research at CAPRISA, presented the results of the HVTN 108 study, a Phase 1 study investigating the safety and immunogenicity of a DNA vaccine, in the plenary session at the meeting


Photo: The CAPRISA  HVTN team at  the CAPRISA eThekwini Research Clinic in Durban. The team received awards for excellent data submission and high participant retention at the HVTN Full Group Meeting held in Washington.